Global market access is entering a decade where evidence will be more measurable, affordability pressure will be more structural, and implementation will be more scrutinized. Therapies are becoming more targeted and more complex to deliver, while payors and HTA bodies are improving their ability to encode policies into digital rules, monitor utilization, and reassess value as new data emerges. The net effect is a higher bar for both proof and practicality: decision makers will demand stronger evidence packages and cleaner implementation plans that reduce friction at the point of care.
20.1 Emerging Trends: RWE, Personalized Medicine, and Digital Health
Three trends are converging: real-world evidence is becoming decision-grade, personalized medicine is expanding the diagnostic gate, and digital health is becoming both an evidence generator and a control mechanism for payors. Together, they reward teams that design evidence and operations as a single system.
Real-world evidence becomes decision-grade: The shift is less about new statistical methods and more about data infrastructure and payer behavior. As linkage across claims, EHRs, labs, and registries improves, payors can test whether utilization stayed within criteria, whether outcomes in routine care align with expectations, and whether budget impact behaved within a plausible range. When measurement is feasible, payors are less willing to accept vague uncertainty. They will increasingly ask: what will be measured, how quickly, and how measurement will change policy if results diverge from expectations.
The implication is that RWE plans must be specific and decision-linked. Start with the payer uncertainty you are trying to reduce: durability, generalizability, responder identification, or real-world resource use. Then define the minimum viable plan: population, endpoint, data source, timing, and intended decision use (policy confirmation, reassessment, or expansion). Avoid broad programs that generate data but do not change coverage decisions. If an endpoint cannot be captured reliably in routine care, do not promise to capture it. Use an alternative safeguard such as targeting discipline, phased access, or a financial risk control that does not require fragile measurement.
Personalized medicine expands diagnostics as an access gate: More therapies will be tied to biomarkers, genotypes, phenotypes, and responder signatures. This can strengthen value per treated patient, but it increases operational complexity and denominator sensitivity. If testing expands quickly, the eligible population can expand quickly. Payors respond with tighter documentation, stricter sequencing, and more explicit eligibility boundaries to protect budgets and prevent inappropriate use.
Market access leaders should treat diagnostics as launch-critical reimbursement work. The therapy and the test are a coupled system. If the test is not paid, not available, not trusted, or too slow, the therapy is effectively inaccessible. Build a diagnostic readiness plan that covers: reimbursement route for the test, accepted assays and labs, turnaround times, documentation formats payors can verify, and a plan to monitor testing rates and equity. When testing access is uneven, drug access becomes inequitable, and inequity becomes both a performance problem and a reputational risk.
Digital health becomes both evidence and control: Remote monitoring, software-enabled adherence, and digital care coordination are increasingly paired with drug therapies, especially where outcomes depend on behavior, monitoring, or early intervention. Payors will evaluate whether the digital component measurably improves outcomes and whether it adds privacy, interoperability, or workflow burden. In parallel, payors will increasingly use digital tools themselves to enforce criteria and renewal rules through automated edits and data-driven utilization management.
Manufacturers should distinguish two access pathways. Adjunct value:Separate reimbursement:
The common thread across these trends is that uncertainty becomes more manageable but less tolerated. When measurement is feasible, payors will demand it. When it is not feasible, payors will demand simple, enforceable safeguards. Access teams must design evidence and operations together.
20.2 Evolution of HTA and Payor Expectations
HTA bodies and payors are not converging on a single global standard, but they are becoming more explicit and more consistent in how they reward strong evidence and penalize uncertainty, budget volatility, and unworkable implementation. Four shifts are most likely to shape access outcomes.
Comparator and pathway rigor increases: Decision makers will continue to insist that evidence speaks to the comparator they fund in practice, not merely to placebo or a non-relevant regimen. This increases pressure for head-to-head evidence where feasible and for disciplined indirect comparisons where not. It also increases the importance of pathway mapping. Payors want to know where the therapy fits, how it will be sequenced, and what criteria will look like when encoded into routine authorization and claims workflows.
Conditionality becomes sharper: Managed entry and conditional reimbursement will remain common for high-cost and high-uncertainty assets, but conditions will become more specific and less negotiable. Vague commitments and open-ended registries will be penalized. Payors will want clear endpoints, data sources, timelines, and reassessment triggers. They will also want evidence that conditions can be executed without delaying therapy initiation or creating disproportionate burden for providers and payer operations.
Budget impact dominates more decisions: Even in systems with cost-effectiveness traditions, near-term affordability often becomes the binding constraint. This drives more explicit targeting, phased rollout, stricter continuation rules, and contract structures that reduce variance risk. Strong access teams will present bounded budget scenarios with transparent drivers: eligible population, uptake curve, duration, discontinuation, switching, and site-of-care dynamics. They will link safeguards directly to those drivers so payors can see how risk is controlled.
Implementability becomes an explicit criterion: Payors and HTA bodies increasingly evaluate whether criteria can be implemented through claims systems, provider workflows, and available data. Policies that look elegant on paper but cannot be operationalized generate denials, delays, and provider abrasion, which then becomes political and reputational risk for payors. Expect more scrutiny of documentation requirements, site-of-care economics, and the feasibility of monitoring and follow-up commitments.
These shifts change the winning package. Successful teams will combine: a clear target population, comparator-aligned evidence, transparent uncertainty handling, bounded affordability scenarios, and an implementation plan that reduces administrative burden. The legacy pattern—win assessment, then fix operations—will be less viable as implementers gain influence in decisions and as criteria enforcement becomes more automated.
Finally, payors will increasingly differentiate manufacturers based on reliability. Consistency of population definitions, discipline in claims, delivery on evidence commitments, and clean contract administration build trust. Trust reduces defensive restrictions and shortens cycles over time.
20.3 AI, Advanced Analytics, and Automation in Market Access
AI will not replace market access judgment, but it will materially change cycle time and quality in three areas: insight generation, content production, and operational control. The advantage will come from using AI to accelerate repeatable work while strengthening transparency, compliance, and learning loops.
Faster scenario iteration: Advanced analytics can improve epidemiology, pathway mapping, and budget scenario modeling by combining multiple data sources and automating sensitivity exploration. This enables faster iteration as new evidence arrives or competitors reset the comparator. Teams that can refresh scenarios quickly will negotiate with clearer trade-offs and will avoid being surprised by variance drivers that payors probe, such as testing rates, persistence, site-of-care shifts, and indication expansion.
Operational intelligence at scale: Denials, delays, and policy drift are often detected too late because information is fragmented across policy trackers, hub workflows, claims, and field feedback. Automation can create a near-real-time early warning system: classify denial reasons, detect changes in payer edits, flag spikes in time to therapy, and route issues to owners with defined service levels. AI can assist with classification and anomaly detection, but the differentiator is governance: who owns the fix, how guidance is updated, and how changes are communicated with version control.
Content acceleration with controls: AI can draft payer-facing summaries, produce first-pass dossier modules, generate structured objection responses, and translate global value narratives into local formats. The risk is uncontrolled variation and over-claiming. High-performing organizations will deploy AI through approved modular content libraries and claim-to-evidence maps, with explicit review workflows, version control, and expiry dates. The aim is not to automate persuasion; it is to automate structured consistency while humans retain responsibility for the claims.
AI introduces risks that must be managed deliberately.
- Hallucination risk:
- Bias risk:
- Privacy risk:
- Auditability risk:
A practical AI operating model for market access has four building blocks: Data foundation:Model governance:Content governance:Operational workflows.
20.4 Scenarios for the Next 5–10 Years in Key Markets
Scenario thinking is more useful than prediction because markets will not evolve in a single direction. Four scenarios capture much of the plausible range, and most markets will express combinations of them.
Scenario 1:
Scenario 2:
Scenario 3:
Scenario 4:
In major markets, these scenarios tend to show up in predictable ways. United States:Europe:Japan:China:Emerging markets:
Across all scenarios, the same investments tend to pay off: stronger evidence-to-policy translation, implementation-grade pathway design, faster monitoring, and tighter global-to-local coherence.
20.5 Building a Future-Proof Market Access Organization
Future-proofing is not predicting policy perfectly. It is building an organization that adapts faster than the environment changes. Five capabilities will differentiate access organizations over the next decade.
Clear decision rights:
Standardized execution:
Credibility as an asset:
Operational excellence as access:
Learning loops and talent:
A practical future-proofing roadmap can be structured as three horizons: Horizon 1:Horizon 2:Horizon 3:
The guiding rule across horizons is design for implementation. Evidence must map to criteria, criteria must map to workflows, and workflows must map to measurable outcomes. The future of global market access will reward organizations that treat reimbursement as both strategy and operations—and that can demonstrate, in real-world performance, that access delivers value without breaking budgets or pathways.
